US 2023/0399407 A1 · FC ALPHA RECEPTOR BINDING ANTIBODY

Abstract

The present invention relates to an antibody having enhanced binding affinity for human Fc alpha receptor and a technique for maximizing a mechanism of antibody action by using same. Antibodies specific for Fc alpha receptors or immunologically active fragments thereof according to the present invention are in the form of IgG and bind to Fc alpha receptors of effector cells, especially, neutrophils, which are most abundant in mammals, thereby overcoming the disadvantages of conventional IgA antibodies and maximizing an effector function in various antibody therapeutic agents, which leads to maximizing the mechanism of antibody action (ADCC and ADCP). Thus, various Fc-fused protein therapeutic agents using same can be advantageously utilized as antibody drugs with enhanced effector functions.

Claims21

Dependent claims

An antibody specific for an Fc alpha receptor or an immunologically active fragment thereof comprising:

(a) a VH domain including complementarity determining region heavy chain (CDRH)1 including any one selected from the group consisting of amino acid sequences of SEQ ID NOs:
1 to 3, CDRH2 including any one selected from the group consisting of amino acid sequences of SEQ ID NOs:
4 to 7, and CDRH3 including any one selected from the group consisting of amino acid sequences of SEQ ID NOs:
8 to 15;
and/or
(b) a VL domain including complementarity determining region light chain (CDRL)1 including any one selected from the group consisting of amino acid sequences of SEQ ID NOs:
16 to 21, CDRL2 including any one selected from the group consisting of amino acid sequences of SEQ ID NOs:
22 to 27, and CDRL3 including any one selected from the group consisting of amino acid sequences of SEQ ID NOs:
28 to 32.

6 more elements

Dependencies are inferred from the claim text.

Fc alpha receptor binding antibody

Life of this patent

Fc alpha receptor binding antibody

Life of this patent

Abstract

Claims21